1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oral Vaccine for Human Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Oral Vaccine for Human by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Oral Vaccine for Human by Country/Region, 2018, 2022 & 2029
2.2 Oral Vaccine for Human Segment by Type
2.2.1 Rotavirus Vaccine
2.2.2 Cholera Vaccine
2.2.3 Oral Polio Vaccine
2.2.4 Other
2.3 Oral Vaccine for Human Sales by Type
2.3.1 Global Oral Vaccine for Human Sales Market Share by Type (2018-2023)
2.3.2 Global Oral Vaccine for Human Revenue and Market Share by Type (2018-2023)
2.3.3 Global Oral Vaccine for Human Sale Price by Type (2018-2023)
2.4 Oral Vaccine for Human Segment by Application
2.4.1 Public
2.4.2 Private
2.5 Oral Vaccine for Human Sales by Application
2.5.1 Global Oral Vaccine for Human Sale Market Share by Application (2018-2023)
2.5.2 Global Oral Vaccine for Human Revenue and Market Share by Application (2018-2023)
2.5.3 Global Oral Vaccine for Human Sale Price by Application (2018-2023)
3 Global Oral Vaccine for Human by Company
3.1 Global Oral Vaccine for Human Breakdown Data by Company
3.1.1 Global Oral Vaccine for Human Annual Sales by Company (2018-2023)
3.1.2 Global Oral Vaccine for Human Sales Market Share by Company (2018-2023)
3.2 Global Oral Vaccine for Human Annual Revenue by Company (2018-2023)
3.2.1 Global Oral Vaccine for Human Revenue by Company (2018-2023)
3.2.2 Global Oral Vaccine for Human Revenue Market Share by Company (2018-2023)
3.3 Global Oral Vaccine for Human Sale Price by Company
3.4 Key Manufacturers Oral Vaccine for Human Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Vaccine for Human Product Location Distribution
3.4.2 Players Oral Vaccine for Human Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Oral Vaccine for Human by Geographic Region
4.1 World Historic Oral Vaccine for Human Market Size by Geographic Region (2018-2023)
4.1.1 Global Oral Vaccine for Human Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Oral Vaccine for Human Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Oral Vaccine for Human Market Size by Country/Region (2018-2023)
4.2.1 Global Oral Vaccine for Human Annual Sales by Country/Region (2018-2023)
4.2.2 Global Oral Vaccine for Human Annual Revenue by Country/Region (2018-2023)
4.3 Americas Oral Vaccine for Human Sales Growth
4.4 APAC Oral Vaccine for Human Sales Growth
4.5 Europe Oral Vaccine for Human Sales Growth
4.6 Middle East & Africa Oral Vaccine for Human Sales Growth
5 Americas
5.1 Americas Oral Vaccine for Human Sales by Country
5.1.1 Americas Oral Vaccine for Human Sales by Country (2018-2023)
5.1.2 Americas Oral Vaccine for Human Revenue by Country (2018-2023)
5.2 Americas Oral Vaccine for Human Sales by Type
5.3 Americas Oral Vaccine for Human Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Vaccine for Human Sales by Region
6.1.1 APAC Oral Vaccine for Human Sales by Region (2018-2023)
6.1.2 APAC Oral Vaccine for Human Revenue by Region (2018-2023)
6.2 APAC Oral Vaccine for Human Sales by Type
6.3 APAC Oral Vaccine for Human Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oral Vaccine for Human by Country
7.1.1 Europe Oral Vaccine for Human Sales by Country (2018-2023)
7.1.2 Europe Oral Vaccine for Human Revenue by Country (2018-2023)
7.2 Europe Oral Vaccine for Human Sales by Type
7.3 Europe Oral Vaccine for Human Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oral Vaccine for Human by Country
8.1.1 Middle East & Africa Oral Vaccine for Human Sales by Country (2018-2023)
8.1.2 Middle East & Africa Oral Vaccine for Human Revenue by Country (2018-2023)
8.2 Middle East & Africa Oral Vaccine for Human Sales by Type
8.3 Middle East & Africa Oral Vaccine for Human Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Vaccine for Human
10.3 Manufacturing Process Analysis of Oral Vaccine for Human
10.4 Industry Chain Structure of Oral Vaccine for Human
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Vaccine for Human Distributors
11.3 Oral Vaccine for Human Customer
12 World Forecast Review for Oral Vaccine for Human by Geographic Region
12.1 Global Oral Vaccine for Human Market Size Forecast by Region
12.1.1 Global Oral Vaccine for Human Forecast by Region (2024-2029)
12.1.2 Global Oral Vaccine for Human Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oral Vaccine for Human Forecast by Type
12.7 Global Oral Vaccine for Human Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Oral Vaccine for Human Product Portfolios and Specifications
13.1.3 Merck Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Oral Vaccine for Human Product Portfolios and Specifications
13.2.3 GSK Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Oral Vaccine for Human Product Portfolios and Specifications
13.3.3 Sanofi Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Lanzhou Institute
13.4.1 Lanzhou Institute Company Information
13.4.2 Lanzhou Institute Oral Vaccine for Human Product Portfolios and Specifications
13.4.3 Lanzhou Institute Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Lanzhou Institute Main Business Overview
13.4.5 Lanzhou Institute Latest Developments
13.5 Serum Institute
13.5.1 Serum Institute Company Information
13.5.2 Serum Institute Oral Vaccine for Human Product Portfolios and Specifications
13.5.3 Serum Institute Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Serum Institute Main Business Overview
13.5.5 Serum Institute Latest Developments
13.6 Valneva
13.6.1 Valneva Company Information
13.6.2 Valneva Oral Vaccine for Human Product Portfolios and Specifications
13.6.3 Valneva Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Valneva Main Business Overview
13.6.5 Valneva Latest Developments
13.7 Shanghai United Cell
13.7.1 Shanghai United Cell Company Information
13.7.2 Shanghai United Cell Oral Vaccine for Human Product Portfolios and Specifications
13.7.3 Shanghai United Cell Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Shanghai United Cell Main Business Overview
13.7.5 Shanghai United Cell Latest Developments
13.8 Bibcol
13.8.1 Bibcol Company Information
13.8.2 Bibcol Oral Vaccine for Human Product Portfolios and Specifications
13.8.3 Bibcol Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bibcol Main Business Overview
13.8.5 Bibcol Latest Developments
13.9 PaxVax
13.9.1 PaxVax Company Information
13.9.2 PaxVax Oral Vaccine for Human Product Portfolios and Specifications
13.9.3 PaxVax Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 PaxVax Main Business Overview
13.9.5 PaxVax Latest Developments
13.10 Vabiotech
13.10.1 Vabiotech Company Information
13.10.2 Vabiotech Oral Vaccine for Human Product Portfolios and Specifications
13.10.3 Vabiotech Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Vabiotech Main Business Overview
13.10.5 Vabiotech Latest Developments
13.11 Tiantan Biological
13.11.1 Tiantan Biological Company Information
13.11.2 Tiantan Biological Oral Vaccine for Human Product Portfolios and Specifications
13.11.3 Tiantan Biological Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Tiantan Biological Main Business Overview
13.11.5 Tiantan Biological Latest Developments
13.12 EuBiologics
13.12.1 EuBiologics Company Information
13.12.2 EuBiologics Oral Vaccine for Human Product Portfolios and Specifications
13.12.3 EuBiologics Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 EuBiologics Main Business Overview
13.12.5 EuBiologics Latest Developments
13.13 Panacea Biotec Ltd
13.13.1 Panacea Biotec Ltd Company Information
13.13.2 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolios and Specifications
13.13.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Panacea Biotec Ltd Main Business Overview
13.13.5 Panacea Biotec Ltd Latest Developments
13.14 Bio-Med
13.14.1 Bio-Med Company Information
13.14.2 Bio-Med Oral Vaccine for Human Product Portfolios and Specifications
13.14.3 Bio-Med Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Bio-Med Main Business Overview
13.14.5 Bio-Med Latest Developments
13.15 Halfkin Bio-Pharmaceuticals
13.15.1 Halfkin Bio-Pharmaceuticals Company Information
13.15.2 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolios and Specifications
13.15.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 Research Findings and Conclusion
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer